FDA Approves Unknown Drug — EXTROVIS

EXTROVIS announced the FDA approval of its ANDA application, a regulatory milestone expected to broaden its commercial portfolio and facilitate market entry into a key therapeutic area. This clearance positions the company to begin generic manufacturing operations, potentially disrupting current pricing structures and capturing a share of the market.